

| | |
|--|---------------------------------------|
| 10.18 Administration of Casirivimab/Imdevimab | Revision Dates |
| Application Licensed Nurses Providing Infusion Therapy in the LTC Facility | Original Date December 2020 |

THE FACILITY MUST ENSURE THAT ALL NURSES RESPONSIBLE FOR THE CARE AND MANAGEMENT OF PATIENTS RECEIVING MONOCLONAL ANTIBODY INFUSIONS ARE KNOWLEDGEABLE AND COMPETENT IN THE ADMINISTRATION PROCEDURES AND THE POTENTIAL COMPLICATIONS ASSOCIATED WITH THIS THERAPY.

To Be Performed By:

Licensed nurses in accordance with state law and facility policy. The nurse shall be competent in the safe delivery of infusion therapy within his or her scope of practice. Competency validation is documented in accordance with organizational policy.

Considerations:

1. Casirivimab/imdevimab is a monoclonal antibody for the treatment of mild to moderate COVID-19. These medications are specifically directed against the spike protein of SARS-CoV-2 and are designed to block the virus' attachment and entry into human cells, thus neutralizing the virus.
2. Casirivimab and imdevimab must be administered together after dilution by IV infusion only.
3. The FDA has issued an Emergency Use Authorization (EUA) to treat mild to moderate COVID-19 in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kg with high risk for progressing to severe COVID-19 and/or hospitalization.
4. This EUA is for the use of the unapproved product casirivimab/imdevimab for the treatment of mild to moderate COVID-19. Patients categorizing as high risk must have at least one of the following criteria:
 - 4.1 Body mass index (BMI) \geq 35
 - 4.2 Chronic kidney disease
 - 4.3 Diabetes
 - 4.4 Immunosuppressive disease
 - 4.5 Currently receiving immunosuppressive treatment
 - 4.6 Are \geq 65 years of age
 - 4.7 Are \geq 55 years of age AND have
 - 4.7.1 Cardiovascular disease OR
 - 4.7.2 Hypertension OR
 - 4.7.3 Chronic obstructive pulmonary disease/other chronic respiratory disease
 - 4.8 Are 12 – 17 years of age AND have
 - 4.8.1 BMI \geq 85th percentile for their age and gender based on CDC growth charts (see reference link at the end of this document) OR
 - 4.8.2 Sickle cell disease OR
 - 4.8.3 Congenital or acquired heart disease OR
 - 4.8.4 Neurodevelopmental disorders, for example, cerebral palsy OR
 - 4.8.5 A medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19) OR

- 4.8.6 Asthma, reactive airway or other chronic respiratory disease that requires daily medication for control
5. Casirivimab/Imdevimab is not authorized for use in patients:
 - 5.1 Who are hospitalized due to COVID-19, OR
 - 5.2 Who require oxygen therapy due to COVID-19, OR
 - 5.3 Oxygen dependent patients who require an increase in oxygen flow rate due to COVID-19 complications
6. Benefit of treatment with casirivimab/imdevimab has not been observed in patients hospitalized due to COVID-19. Monoclonal antibodies, such as casirivimab/imdevimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation.
7. Monoclonal Antibodies and COVID-19 Vaccines¹:
 - 7.1 Currently, there is no data on the safety and efficacy of Pfizer-BioNTech COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment.
 - 7.2 Based on the estimated half-life of such therapies, as well as evidence suggesting that reinfection is uncommon in the 90 days after initial infection, vaccination should be deferred for at least 90 days, as a precautionary measure, until additional information becomes available, to avoid interference of the antibody treatment with vaccine-induced immune responses.
8. Healthcare providers should review the **Fact Sheet for Healthcare Providers** for information on the authorized use of casirivimab and imdevimab and mandatory requirements of the EUA and must comply with the requirements of the EUA. The **FDA Letter of Authorization** is available here for reference, as well as the **Dear Healthcare Provider Letter** and **Patient Fact Sheet**.
9. The prescribing health care provider and/or the provider's designee are/is responsible for mandatory reporting of all medication errors and adverse events (death, serious adverse events) potentially related to casirivimab/imdevimab treatment within 7 calendar days from the onset of the event. The reports should include unique identifiers and the words **"Casirivimab and imdevimab under Emergency Use Authorization (EUA)" in the description section of the report.**
 - 9.1 Submit adverse event reports to FDA MedWatch using one of the following methods:
 - 9.1.1 Complete and submit the report online: www.fda.gov/medwatch/report.htm
 - 9.1.2 By using a postage-paid Form FDA 3500 available at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM163919.pdf> and returning by mail (MedWatch, 5600 Fishers Lane, Rockville, MD 20852-9787), or by fax (1-277 800-FDA-0178)
 - 9.1.3 Call 1-800-FDA-1088 to request a reporting form
 - 9.1.4 Submitted reports should include in the field name, "Describe Event, Problem, or Product Use/ Medication Error" a statement "Casirivimab and imdevimab treatment under Emergency Use Authorization (EUA)."
 - 9.1.5 OTHER REPORTING REQUIREMENTS:
In addition, please provide a copy of all FDA MedWatch forms to:
Regeneron Pharmaceuticals, Inc
Fax: 1-888-876-2736
E-mail: medical.information@regeneron.com
Or call Regeneron Pharmaceuticals at 1-844-734-6643 to report adverse events.
 - 9.2 Serious Adverse Events are defined as:
 - 9.2.1 Death
 - 9.2.2 A life-threatening adverse event
 - 9.2.3 Inpatient hospitalization or prolongation of existing hospitalization

¹ https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/clinical-considerations.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2F%2Finfo-by-manufacturer%2Fpfizer%2Fclinical-considerations.html

- 9.2.4 A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions
 - 9.2.5 A congenital anomaly/birth defect
 - 9.2.6 A medical or surgical intervention to prevent death, a life-threatening event, hospitalization, disability, or congenital anomaly
10. Licensed nurses caring for patients receiving infusion therapies are expected to follow infection prevention procedures.

Guidance

1. Casirivimab/Imdevimab is administered as a single intravenous infusion of 1,200 mg of casirivimab AND 1,200 mg of imdevimab over a minimum of 60 minutes, as soon as possible after a positive COVID-19 test and within 10 days of symptom onset.
 - 1.1 Consider slower infusion rate for patients with CHF, chronic kidney disease, and Systemic Inflammatory Response Syndrome (SIRS)
 - 1.2 Casirivimab and imdevimab solutions must be diluted prior to administration
2. There is a potential for serious hypersensitivity reaction, including anaphylaxis with the administration of casirivimab/imdevimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue and initiate appropriate medications and/or supportive therapy.
 - 2.1 Anaphylaxis and infusion-related orders must be obtained prior to infusion
 - 2.2 Anaphylaxis kit/medications must be readily available
3. The casirivimab/imdevimab infusion should be followed by administration of **25 mL** 0.9% Sodium Chloride to clear the medication from the administration set, ensuring the complete dose is administered. A physician/LIP order must be obtained for this solution, at the same rate as the medication.
4. Casirivimab/imdevimab is available as concentrated solution and must be diluted prior to administration.
5. Casirivimab/imdevimab vial or compounded medications must be removed from the refrigerator approximately 20-30 minutes prior to admixing or administration to bring to room temperature. Do not expose to direct heat and do not shake the vials.
 - 5.1 **Prior to admixing or removing from refrigerator, confirm the presence of a patent vascular access device**
6. Inspect for particulate matter and discoloration. Solution is slightly opalescent and colorless to pale yellow. Do not use if particulate matter identified.
7. Do not freeze, shake or expose to direct light.
8. Monitor patient during administration and for at least one hour post infusion. Signs and symptoms of infusion-related reactions may include fever, chills, nausea, headache, bronchospasm, hypotension, angioedema, throat irritation, rash including urticarial, pruritus, myalgia, and dizziness.
9. Monitor vital signs:
 - 9.1 Prior to initiating infusion
 - 9.2 Every 15 minutes during infusion
 - 9.3 Every 15 minutes for 1 hour post infusion
10. If an infusion-related reaction occurs, consider slowing or stopping the infusion and administer appropriate medications and supportive care per prescriber's orders. Stop infusion for signs and symptoms of clinically significant hypersensitivity reaction or if anaphylaxis occurs.

11. Administration set with 0.2 or 0.22 micron in-line filter provided by the pharmacy must be used. Use of electronic infusion device for medication administration is recommended.
12. No dosage adjustment is recommended in pregnant or lactating women and in patients with renal impairment.
13. Patients treated with casirivimab/imdevimab should continue to self-isolate and use infection control measures (e.g., wear mask, isolate, social distance, avoid sharing personal items, clean and disinfect "high touch" surfaces, and frequent handwashing) according to CDC guidelines.
14. Use strict aseptic technique/precautions, when admixing and during administration of this medication as there are no preservatives or any bacteriostatic agents in the products.
15. Patient with known hypersensitivity to any ingredient of casirivimab/imdevimab must not receive casirivimab/imdevimab.
16. As the healthcare provider, communicate to your patient or parent/caregiver, as age appropriate, information consistent with the "Fact Sheet for Patients, Parents and Caregivers" prior to the patient receiving casirivimab/imdevimab. Healthcare providers (to the extent practicable given the circumstances of the emergency) must document in the patient's medical record that the patient/caregiver has been:
 - 16.1 Provided the "Fact Sheet for Patients, Parents and Caregivers"
 - 16.2 Informed of alternatives to receiving authorized casirivimab/imdevimab
 - 16.3 Informed that casirivimab/imdevimab is an unapproved drug that is authorized for use under this Emergency Use Authorization

Equipment if facility is admixing medication:

- Medication vials (one 11.1mL vial, or four 2.5mL vials of each medication)
- 2 – 10 mL syringes (for drawing up medications from each vial)
- 1 – 20 mL syringe (for withdrawal of fluid from minibag)
- 250 mL minibag of 0.9% sodium chloride
- Medication added label
- Alcohol pads
- 3- safety engineered needles (20 gauge)
- 50-100 mL minibag of 0.9% sodium chloride for clearing medication from administration set
- Prescribed flushing/locking agent(s) in 10 mL barrel diameter or larger syringe
- Electronic infusion device
- Administration set with a 0.2 or 0.22 micron filter
- Clean gloves

Equipment if pharmacy is admixing medication:

- Compounded medication bag
- 50-100 mL minibag of 0.9% sodium chloride for clearing medication from administration set
- Alcohol pads
- Prescribed flushing/locking agent(s) in 10 mL barrel diameter or larger syringe, if appropriate
- Electronic infusion device
- Administration set with 0.2 or 0.22 micron filter
- Clean gloves

Procedure:

1. Verify physician/LIP order. Perform pre-infusion vital sign assessment.
2. Assemble equipment and supplies on clean work surface.

3. Perform hand hygiene. Don clean gloves.
4. Prior to removing medication from the refrigerator, establish vascular access or verify patency of vascular access device. (Refer to procedure 4.1 Short Peripheral Catheter Insertion)
5. **If pharmacy is admixing medication remove medication bag from refrigerator and allow to reach room temperature for approximately 30 minutes. Proceed to step 8.**
6. **If facility is admixing medication:** Remove casirivimab/imdevimab vials from refrigerator and allow to reach room temperature for approximately 20 minutes before preparation. **Do not expose to direct heat. Do not shake the vials.**
7. Casirivimab/imdevimab vials come in liquid form. Admix casirivimab/imdevimab using aseptic technique:
 - 7.1 Inspect casirivimab and imdevimab vials visually for particulate matter and discoloration. Should either be observed, the vials must be discarded.
 - 7.1.1 The solution for each vial should be clear to slightly opalescent, colorless to pale yellow
 - 7.2 Obtain an IV infusion bag containing 250 mL of 0.9% Sodium Chloride; withdraw and discard 20 mL, leaving 230mL in the bag. This is performed prior to adding casirivimab and imdevimab. (Note: must vigorously scrub the vial stoppers and minibag rubber injection port with new alcohol wipe prior to each access.)
 - 7.3 Withdraw **10 mL (1200mg)** of casirivimab and **10 mL (1200mg)** of imdevimab from each respective vial using **two** separate syringes and inject both medications, one after the other, (scrubbing in between with alcohol wipe) into the infusion bag containing 0.9% Sodium Chloride Injection. Discard any product remaining in the vial.
 - 7.4 Gently invert infusion bag by hand approximately 10 times. **Do not shake.** This product is preservative-free and therefore, the diluted infusion solution should be administered immediately.
 - 7.5 Complete and affix medication added label to the bag

NOTE: Casirivimab and imdevimab carton and vial labels may instead be labeled **REGN10933** and **REGN10987** respectively.

8. The prepared infusion solution should not be administered simultaneously with any other medication. The compatibility of casirivimab and imdevimab injection with IV solutions and medications other than 0.9% Sodium Chloride Injection is not known.
9. Attach admixed medication bag to filtered administration set and administer immediately. Program infusion pump to infuse over a minimum of 60 minutes. Program in BASIC mode when using SIGMA Spectrum™ infusion pump. (Refer to procedure 3.6, Administration of an Intermittent Infusion for administration steps.)
10. Monitor patient during administration and for at least one hour post infusion performing patient assessment/ vital signs every 15 minutes. Signs and symptoms of infusion-related reactions may include fever, chills, nausea, headache, bronchospasm, hypotension, angioedema, throat irritation, rash including urticarial, pruritus, myalgia, and dizziness.
11. If an infusion-related reaction occurs, consider slowing or stopping the infusion and administer appropriate medications and/or supportive care. Stop infusion for signs and symptoms of clinically significant hypersensitivity reaction or if anaphylaxis occurs.
12. Upon completion of casirivimab/imdevimab infusion, replace empty medication bag with a 50 - 100 mL 0.9% Sodium Chloride minibag. This will be used to clear administration set of medication ensuring the complete dose has been administered. Administer 0.9% Sodium Chloride at same rate as infusion for a volume of **25 mL** (reset the volume to be infused on the infusion pump at 25 mL). Continue infusion.

13. Upon completion of infusion, perform hand hygiene.
14. Don gloves.
15. Close the clamp and disconnect the administration set from needleless connector.
16. Perform a vigorous mechanical scrub to manually disinfect the needleless connector. Allow to air dry. Follow with prescribed flushing/locking solution, if vascular access device is to remain intact.
17. Dispose of used supplies per facility policy.
18. Remove gloves.
19. Perform hand hygiene.
20. Documentation in the medical record includes, but is not limited to:
 - 20.1 Date and time
 - 20.2 Medications/solution
 - 20.3 Rate and method of infusion
 - 20.4 Prescribed flushing/locking agent(s)
 - 20.5 Site assessment
 - 20.6 Complications and interventions
 - 20.7 Patient response to procedure and/or medication
 - 20.8 Patient/significant other teaching

References:

1. Regeneron webpage for casirivimab/imdevimab: <https://www.regeneron.com/casirivimab-imdevimab> (accessed 12/16/2020)
2. Casirivimab/imdevimab Fact Sheet for Healthcare Providers: <https://www.fda.gov/media/143892/download> (accessed 12/16/2020)
3. FAQ on EUA of casirivimab/imdevimab: <https://www.fda.gov/media/143894/download> (accessed 12/16/2020)
4. https://www.cdc.gov/growthcharts/clinical_charts.htm, Accessed Dec 16, 2020
5. FDA.gov website. Casirivimab Imdevimab treatment-covid19-eua-fact-sheet-for-patient. <https://www.fda.gov/media/143893/download> Accessed Dec 30, 2020.